MNKD Material Contracts | MANNKIND CORP

MANNKIND CORP Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-05-06: Form 10-Q; Exhibit 10.3; Description SIXTH AMENDMENT.
2026-05-06: Form 10-Q; Exhibit 10.2; Description FIFTH AMENDMENT.
2026-05-06: Form 10-Q; Exhibit 10.1; Description Seventh Amendment to Commercial Supply Agreement, dated January 7, 2026, by and between MannKind Corporation and United Therapeutics Corporation (incorporated by reference to Exhibit 10.37 to MannKind Corporation’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026)..
2026-02-26: Form 10-K; Exhibit 10.37; Description Seventh Amendment to Commercial Supply Agreement, dated January 7, 2026, by and between MannKind Corporation and United Therapeutics Corporation..

Filed	Form	Exhibit	Description
2026-05-06	10-Q	10.3	SIXTH AMENDMENT
2026-05-06	10-Q	10.2	FIFTH AMENDMENT
2026-05-06	10-Q	10.1	Seventh Amendment to Commercial Supply Agreement, dated January 7, 2026, by and between MannKind Corporation and United Therapeutics Corporation (incorporated by reference to Exhibit 10.37 to MannKind Corporation’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026).
2026-02-26	10-K	10.37	Seventh Amendment to Commercial Supply Agreement, dated January 7, 2026, by and between MannKind Corporation and United Therapeutics Corporation.
2026-02-26	10-K	10.27	License and Collaboration Agreement, dated September 3, 2018, by and between MannKind Corporation and United Therapeutics.
2025-11-05	10-Q	10.2	Loan Agreement, dated August 6, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto (incorporated by reference to Exhibit 10.2 to MannKind’s Quarterly Report on Form 10-Q (File No. 000-50865), filed with the SEC on August 6, 2025).
2025-11-05	10-Q	10.1	First Amendment to License and Collaboration Agreement dated August 24, 2025 between MannKind Corporation and United Therapeutics Corporation (incorporated by reference to Exhibit 10.1 to MannKind’s Current Report on Form 8-K (File No. 000-50865), filed with the SEC on August 27, 2025).
2025-10-09	8-K	10.1	Contingent Value Rights Agreement, dated as of October 7, 2025, by and between MannKind Corporation and Broadridge Corporate Issuer Solutions, LLC.
2025-08-27	8-K	10.1	First Amendment to License and Collaboration Agreement dated August 24, 2025 between MannKind Corporation and United Therapeutics Corporation
2025-08-25	8-K	10.2	Amendment No.1 to the Loan Agreement, dated August 24, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto.
2025-08-25	8-K	10.1	Form of Tender and Support Agreement.
2025-08-06	10-Q	10.2	Loan Agreement, dated August 6, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto.
2025-08-06	10-Q	10.1	Transition and Separation Agreement, dated May 14, 2025, by and between the Company and Burkhard Blank.
2025-05-08	10-Q	10.3	Sixth Amendment to Commercial Supply Agreement, dated December 2, 2024, by and between MannKind and United Therapeutics Corporation.
2025-05-08	10-Q	10.2	Fifth Amendment to Commercial Supply Agreement, dated January 8, 2024, by and between MannKind and United Therapeutics Corporation.
2025-05-08	10-Q	10.1	Non-Employee Director Compensation Policy.
2024-11-07	10-Q	10.3	Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation.
2024-11-07	10-Q	10.2	Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc.
2024-11-07	10-Q	10.1	Second Amendment to Supply Agreement, dated November 9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc.
2024-03-26	8-K	10.1	Offer Letter, dated March 25, 2024, between MannKind Corporation and Chris Prentiss.
2024-02-27	10-K	10.29	License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics.
2024-02-27	10-K	10.6	Offer Letter, dated September 19, 2022, by and between MannKind Corporation and Burkhard Blank.
2024-02-27	10-K	10.4	Offer Letter, dated May 16, 2023, by and between MannKind Corporation and Sanjay Singh.
2023-08-07	10-Q	10.2	MannKind Corporation 2004 Employee Stock Purchase Plan, as amended.
2023-08-07	10-Q	10.1	MannKind Corporation 2018 Equity Incentive Plan, as amended.
2023-03-27	8-K	10.1	Offer Letter, dated March 21, 2023, by and between MannKind Corporation and Lauren M. Sabella.
2023-02-23	10-K	10.53	First Amendment to Office Lease, date February 11, 2019, by and between Valeritas, Inc. and BRP 293 Equity Partners, LLC.
2023-02-23	10-K	10.52	Office Lease, dated May 10, 2017, by and between Valeritas, Inc. and RFP Lincoln 293 LLC.
2023-02-23	10-K	10.51	Fourth Amendment to Commercial Supply Agreement, dated December 22, 2022, by and between MannKind Corporation and United Therapeutics Corporation.
2023-02-23	10-K	10.50	Third Amendment to Commercial Supply Agreement, dated August 31, 2022, by and between MannKind Corporation and United Therapeutics Corporation.
2023-02-23	10-K	10.49	Second Amendment to Commercial Supply Agreement, dated June 15, 2022, by and between MannKind Corporation and United Therapeutics Corporation.
2023-02-23	10-K	10.43	Amendment No. 9 to Credit and Security Agreement, dated November 8, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust.
2023-02-23	10-K	10.42	Amendment No. 8 to Credit and Security Agreement, dated November 3, 2021, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust.
2022-11-08	10-Q	10.1	Amendment No. 10 to the Credit and Security Agreement, dated August 29, 2022, by and among MannKind Corporation, MannKind LLC, QrumPharma, Inc., and MidCap Financial Trust.
2022-05-05	10-Q	10.1	Amendment No. 1 to Office Lease, dated April 8, 2022, between MannKind Corporation and Russell Ranch Road II LLC.
2021-11-09	10-Q	10.3	Purchase and Sale Agreement, dated September 23, 2021, by and between MannKind Corporation and 1 Casper, LLC.
2021-11-09	10-Q	10.2	First Amendment to Commercial Supply Agreement, dated October 16, 2021, by and between MannKind Corporation and United Therapeutics Corporation.
2021-11-09	10-Q	10.1	Commercial Supply Agreement, dated August 12, 2021, by and between MannKind Corporation and United Therapeutics Corporation.
2021-02-25	10-K	10.23	Supply Agreement, dated as of July 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals S.A.S.
2021-02-25	10-K	10.5	Offer Letter, dated August 11, 2003, by and between MannKind and Joseph Kocinsky.
2021-02-25	10-K	10.4	Offer Letter, dated May 7, 2020 by and between MannKind and Alejandro Galindo.
2020-08-05	10-Q	10.1	MannKind Corporation 2018 Equity Incentive Plan, as amended.
2019-02-26	10-K	10.50	Fourth Amendment to Supply Agreement, dated December 24, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc.
2019-02-26	10-K	10.15	Non-Employee Director Compensation Program.
2018-11-01	10-Q	10.9	Research Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation.
2018-11-01	10-Q	10.8	License and Collaboration Agreement, dated September 3, 2018 by and between MannKind and United Therapeutics Corporation.
2018-05-09	10-Q	10.8	Third Amendment to Supply Agreement, dated April 11, 2018, by and between MannKind and Amphastar Pharmaceuticals, Inc.
2018-02-27	10-K	10.47	Controlled Equity OfferingSM Sales Agreement, by and between MannKind and Cantor Fitzgerald & Co., dated February 27, 2018.
2018-02-27	10-K	10.16	Non-Employee Director Compensation Program.
2018-02-27	10-K	10.6	Offer Letter dated February 2, 2018, by and between MannKind and David Kendall.
2018-02-27	10-K	10.5	Offer Letter dated June 28, 2017, by and between MannKind and Patrick McCauley.
2018-02-27	10-K	10.4	Offer Letter dated February 17, 2017, by and between MannKind and Courtney Barton.
2017-08-07	10-Q	10.3	Office Lease, dated May 5 2017, by and between MannKind and Russell Ranch Road II LLC.
2017-03-16	10-K	10.36	Offer Letter dated December 22, 2016, by and between MannKind and Stuart Tross.
2017-03-16	10-K	10.35	First, Second and Third Amendments to Agreement of Purchase and Sale and Joint Escrow Instructions, dated February 7, 2017, February 10, 2017 and February 15, 2017, respectively, by and between MannKind and Rexford Industrial Realty, L.P.
2017-03-16	10-K	10.33	Second Amendment to Supply Agreement, dated November 9, 2016, by and between MannKind and Amphastar Pharmaceuticals, Inc.
2017-03-16	10-K	10.32	First Amendment to Supply Agreement, dated October 31, 2014, by and between MannKind and Amphastar France Pharmaceuticals, S.A.S. and Amphastar Pharmaceuticals, Inc.
2017-03-16	10-K	10.31	Settlement Agreement, dated November 9, 2016, by and among MannKind, Technosphere International C.V., MannKind Netherlands B.V. and Sanofi-Aventis U.S. LLC.
2016-08-09	10-Q	10.1	MannKind Corporation 2013 Equity Incentive Plan, as amended.
2016-03-15	10-K	10.38	Offer Letter, dated March 9, 2016, by and between MannKind and Michael Castagna.
2016-03-15	10-K	10.37	Sublease Agreement, dated May 1, 2015, by and between MannKind and the Alfred Mann Foundation for Scientific Research.
2016-03-15	10-K	10.36	Separation Agreement, dated December 1, 2015, by and between MannKind and Hakan S. Edstrom.
2016-03-15	10-K	10.8	Separation Agreement, dated March 11, 2016, by and between MannKind and Juergen Martens.
2015-05-11	10-Q	10.1	Transition and Separation Agreement, dated March 20, 2015, by and between MannKind Corporation and Diane Palumbo
2014-11-10	10-Q	10.3	Supply Agreement, dated as of July 31, 2014, by and between MannKind Corporation and Amphastar France Pharmaceuticals S.A.S.
2014-11-10	10-Q	10.2	Supply Agreement, dated as of August 11, 2014, by and between MannKind Corporation and Sanofi-Aventis Deutschland GmbH.
2014-11-10	10-Q	10.1	License and Collaboration Agreement, dated as of August 11, 2014, by and among MannKind Corporation, Technosphere International C.V., MannKind Netherlands B.V. and Sanofi-Aventis Deutschland GmbH.
2014-03-03	10-K	10.39	First Amendment to Facility Agreement and Registration Rights Agreement, dated as of February 28, 2014, by and among Mannkind, Deerfield Private Design Fund II, L.P., and Deerfield Private
2014-03-03	10-K	10.32	At-The-Market Issuance Sales Agreement, dated March 3, 2014, by and between MannKind and Meyers Associates, L.P. (doing business as Brinson Patrick, a division of Meyers Associates, L.P.).
2014-03-03	10-K	10.31	At-The-Market Issuance Sales Agreement, dated March 3, 2014, by and between MannKind and MLV & Co. LLC.
2013-08-09	10-Q	10.1	Non-Employee Director Compensation Program.
2013-03-18	10-K	10.39	At-The-Market Issuance Sales Agreement, dated March 18, 2013, by and between MannKind and Brinson Patrick Securities Corporation.
2013-03-18	10-K	10.38	At-The-Market Issuance Sales Agreement, dated March 18, 2013, by and between MannKind and MLV & Co. LLC.
2012-10-19	8-K	10.2	AMENDMENT AND RESTATED PROMISSORY NOTE
2012-10-19	8-K	10.1	COMMON STOCK AND WARRANT PURCHASE AGREEMENT
2012-07-03	8-K	10.1	AMENDED AND RESTATED PROMISSORY NOTE
2012-05-10	10-Q	10.3	AMENDMENT, DATED MAY 9, 2012, TO AMENDED AND RESTATED PROMISSORY NOTE
2012-02-06	8-K	10.1	COMMON STOCK PURCHASE AGREEMENT
2012-01-20	8-K	10.1	AMENDMENT TO AMENDED AND RESTATED PROMISSORY NOTE
2011-08-04	10-Q	10.3	Letter Agreement, dated June 24, 2011, between MannKind and N.V. Organon
2011-08-04	10-Q	10.2	Employment Agreement, dated June 27, 2011, between MannKind and Dr. Peter C. Richardson
2010-08-11	8-K	10.4	Amended and Restated Promissory Note made by MannKind Corporation in favor of The Mann Group LLC, dated August 10, 2010.
2010-08-11	8-K	10.3	Common Stock Purchase Agreement by and between MannKind Corporation and The Mann Group LLC, dated August 10, 2010.
2010-08-11	8-K	10.2	Letter Agreement by and between MannKind Corporation and Omni Capital Corporation, dated August 10, 2010.
2010-08-11	8-K	10.1	Common Stock Purchase Agreement by and between MannKind Corporation and Seaside 88, LP, dated August 10, 2010.
2009-02-27	10-K	10.1	Promissory Note made by MannKind in favor of The Mann Group LLC dated February 26, 2009.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Alto Neuroscience, Inc. (ANRO)	United States	$1.065B	-11.02
Savara Inc (SVRA)	United States	$1.044B	-9.10
MoonLake Immunotherapeutics (MLTX)	Switzerland	$1.031B	-5.43
Pacira BioSciences, Inc. (PCRX)	United States	$1.020B	69.03
Janux Therapeutics, Inc. (JANX)	United States	$1.019B	-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)	United States	$1.116B	10.93
Corvus Pharmaceuticals, Inc. (CRVS)	United States	$0.994B	-23.25
Seaport Therapeutics, Inc. (SPTX)	United States	$1.131B
Kura Oncology, Inc. (KURA)	United States	$0.967B	-3.29
Arbutus Biopharma Corp (ABUS)		$0.965B	6.19